Efficacy of IDOR‐1117‐2520, a novel, orally available CCR6 antagonist in preclinical models of skin dermatitis
Authors:
Open Access
- 28 March 2025
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 182 (15) , 3452-3475
Abstract
Background and Purpose: The chemokine receptor CCR6 guides pathogenic T17 cells, implicated in autoimmune diseases including psoriasis, to sites of inflammation via the chemokine CCL20. Therefor, pharmacological inhibition of CCR6+ immune cell migration provides a novel therapeutic approach. Translatability of such an intervention has not yet been assessed in detail. We evaluated the translatability of the Aldara® mouse model induced skin inflammation to psoriasis, with particular focus on immune cell trafficking and assessed the efficacy of IDOR‐1117‐2520, a highly selective, potent and orally available CCR6 small inhibitor.Experimental Approach: Effects of IDOR‐1117‐2520 were investigated in the Aldara® and IL23 mouse models of skin inflammation using flow cytometry, RNA sequencing and transcriptome‐based cell type deconvolution approaches to characterise immune cell migration patterns. These results were compared to human psoriasis transcriptomics data.Key Results: IDOR‐1117‐2520 dose dependently reduced infiltration of CCR6+ immune cells into inflamed skin, and was equally efficacious as IL‐17 and IL‐23 inhibition in models of skin inflammation. Pathway analysis showed molecular similarities in the immune response between human psoriasis and the Aldara® mouse model. IL‐17/IL‐23 pathway genes were expressed in both human psoriasis and the mouse model. CCR6 inhibition modulated multiple pathways associated with inflammation beyond the proximal IL‐17/IL‐23 pathway. A chemokine–chemokine receptor interaction map implicated CCL20‐CCR6 as the dominant axis in recruiting pathogenic T17 cells in both the model and in human psoriasis.Conclusion and Implications: IDOR‐1117‐2520 could provide a promising novel targeted approach to treating psoriasis and, potentially, other autoimmune diseases involving the CCR6/CCL20 axis and the IL‐17/IL‐23 pathway. IDOR‐1117‐2520 is currently being evaluated in a clinical phase 1 trial (ISRCTN28892128).Keywords
This publication has 65 references indexed in Scilit:
- Role of the CXCR6/CXCL16 axis in autoimmune diseasesInternational Immunopharmacology, 2023
- Multi‐omics integration reveals a core network involved in host defence and hyperkeratinization in psoriasisClinical and Translational Medicine, 2022
- CCR6-CCL20 axis as a therapeutic target for autoimmune diseasesAutoimmunity Reviews, 2021
- Single-Cell Profiling Reveals Divergent, Globally Patterned Immune Responses in Murine Skin InflammationiScience, 2020
- Pathophysiology, Clinical Presentation, and Treatment of PsoriasisJAMA, 2020
- Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trialsJournal of the American Academy of Dermatology, 2020
- IL‐23‐ and Imiquimod‐Induced Models of Experimental Psoriasis in MiceCurrent Protocols in Immunology, 2019
- Pathological roles of the homeostatic chemokine CXCL12Cytokine & Growth Factor Reviews, 2018
- Transcriptional determinants of individualized inflammatory responses at anatomically separate sitesJournal of Allergy and Clinical Immunology, 2018
- Activation of the Aryl Hydrocarbon Receptor Dampens the Severity of Inflammatory Skin ConditionsImmunity, 2014